Duality Advisers’s Haemonetics HAE Stock Holding History

Duality Advisers’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,415	Closed	-$426K	–	641
2022 Q4	$426K	Buy	+5,415	New	+$435K	0.05%	468
2022 Q1	–	Sell	-42,637	Closed	-$2.26M	–	709
2021 Q4	$2.26M	Buy	+42,637	New	+$2.6M	0.24%	155
2021 Q3	–	Sell	-58,671	Closed	-$3.91M	–	606
2021 Q2	$3.91M	Buy	58,671 +29,777	+103%	+$2.11M	0.35%	85
2021 Q1	$3.21M	Buy	+28,894	New	+$3.58M	0.28%	116
2020 Q1	–	Sell	-35,745	Closed	-$4.11M	–	140
2019 Q4	$4.11M	Buy	+35,745	New	+$4.33M	0.25%	141

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Duality Advisers's HAE Position: Q1 2023 in Review

Duality Advisers sold out of Haemonetics (HAE) in Q1 2023, closing a stake of 5,415 shares — an estimated $426K sold.

Duality Advisers first reported a position in HAE in Q4 2019 and held it in 5 quarters. The position peaked at $4.11M in Q4 2019. 300 funds tracked by Wall St. Rank hold HAE as of Q1 2023.

Duality Advisers reported no remaining Haemonetics position as of Q1 2023 after selling out during the quarter.
Duality Advisers sold 5,415 Haemonetics shares in Q1 2023, an estimated $426K.
Duality Advisers first reported a position in Haemonetics in Q4 2019 and held it in 5 quarters.
Duality Advisers's Haemonetics position peaked at $4.11M in Q4 2019.
300 funds tracked by Wall St. Rank held Haemonetics as of Q1 2023.

Based on Duality Advisers's 13F filing for Q1 2023, filed 27 Jun 2023.